-
1
-
-
4644301804
-
Progress report on new antiepileptic drugs: A summary of the Seventh Eilat conference on new antiepileptic drugs (EILAT VII)
-
Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat conference on new antiepileptic drugs (EILAT VII). Epilepsy Res. 2004;61:1-48.
-
(2004)
Epilepsy Res
, vol.61
, pp. 1-48
-
-
Bialer, M.1
Johannessen, S.I.2
Kupferberg, H.J.3
-
2
-
-
0034091545
-
The new antiepileptic drugs: Pharmacological and clinical aspects
-
Perucca E. The new antiepileptic drugs: pharmacological and clinical aspects. Curr Pharm Des. 2000;6:839-860.
-
(2000)
Curr Pharm Des
, vol.6
, pp. 839-860
-
-
Perucca, E.1
-
3
-
-
0029978025
-
The impact of new antiepileptic drugs on the prognosis of epilepsy: Seizure freedom should be the ultimate goal
-
Walker MC, Sander JWAS. The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology. 1996;46:912-914.
-
(1996)
Neurology
, vol.46
, pp. 912-914
-
-
Walker, M.C.1
Sander, J.W.A.S.2
-
4
-
-
0038205341
-
General principles: Combination therapy and drug interactions
-
Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Philadelphia: Lippincott Williams & Wilkins, and other chapters therein on the various new AEDs
-
Perucca E, Levy RH. General principles: Combination therapy and drug interactions. In Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002, pp 96-102, and other chapters therein on the various new AEDs.
-
(2002)
Antiepileptic Drugs, 5th Ed.
, pp. 96-102
-
-
Perucca, E.1
Levy, R.H.2
-
5
-
-
0002482059
-
General principles: Drug absorption, distribution and elimination
-
Levy RH, Mattson RH, Meldrum BS, eds. New York: Raven Press
-
Levy RH, Thummel KE, Unadkat JD. General principles: Drug absorption, distribution and elimination. In Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs, 4th ed. New York: Raven Press, 1995, pp 13-30.
-
(1995)
Antiepileptic Drugs, 4th Ed.
, pp. 13-30
-
-
Levy, R.H.1
Thummel, K.E.2
Unadkat, J.D.3
-
8
-
-
0012525623
-
Drugs as inducers of metabolic enzymes: Phenobarbital, phenytoin and carbamazepine
-
Levy RH, Thummel KE, Trager WF, Hansten PD, Eiehelbaum M, eds. Philadelphia: Lippincott, and other chapters therein
-
Abdel-Rhaman SM, Leeders JS. Drugs as inducers of metabolic enzymes: phenobarbital, phenytoin and carbamazepine. In Levy RH, Thummel KE, Trager WF, Hansten PD, Eiehelbaum M, eds. Metabolic Drug Interactions. Philadelphia: Lippincott, 2000, pp 673-690, and other chapters therein.
-
(2000)
Metabolic Drug Interactions
, pp. 673-690
-
-
Abdel-Rhaman, S.M.1
Leeders, J.S.2
-
9
-
-
0031800865
-
A mechanistic approach to drug interactions
-
Anderson GA. A mechanistic approach to drug interactions. Ann Pharmacother. 1998;32:554-563.
-
(1998)
Ann Pharmacother
, vol.32
, pp. 554-563
-
-
Anderson, G.A.1
-
10
-
-
0028787051
-
Cytochrome P450 isozymes and antiepileptic drug interactions
-
Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia. 1995;36(Suppl. 5):S8-S13.
-
(1995)
Epilepsia
, vol.36
, Issue.5 SUPPL.
-
-
Levy, R.H.1
-
11
-
-
0002936892
-
Prediction of drug interactions from in vitro studies: Basic principles - From in vitro to in vivo; an academic perspective
-
Levy RH, et al, eds. Philadelphia: Lippincott
-
Levy RH, Trager WF. Prediction of drug interactions from in vitro studies: Basic principles - from in vitro to in vivo; an academic perspective. In Levy RH, et al, eds. Metabolic Drug Interactions. Philadelphia: Lippincott, 2000, pp 21-28.
-
(2000)
Metabolic Drug Interactions
, pp. 21-28
-
-
Levy, R.H.1
Trager, W.F.2
-
12
-
-
0034042711
-
Induction of drug metabolizing enzymes: Pharmacokinetic and toxicological consequences in humans
-
Fuhr U. Induction of drug metabolizing enzymes: pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet. 2000;38:493-504.
-
(2000)
Clin Pharmacokinet
, vol.38
, pp. 493-504
-
-
Fuhr, U.1
-
13
-
-
0033972441
-
Pharmacokinetic - Pharmacodynamic consequences and clinical relevance of cytochrome 3A4 inhibition
-
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic - pharmacodynamic consequences and clinical relevance of cytochrome 3A4 inhibition. Clin Pharmacokinet. 2000;38:41-57.
-
(2000)
Clin Pharmacokinet
, vol.38
, pp. 41-57
-
-
Dresser, G.K.1
Spence, J.D.2
Bailey, D.G.3
-
15
-
-
20144373179
-
Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in presence and absence of enzyme induction by carbamazepine
-
Britzi M, Perucca E, Soback S, et al. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in presence and absence of enzyme induction by carbamazepine. Epilepsia. 2005;46:378-384.
-
(2005)
Epilepsia
, vol.46
, pp. 378-384
-
-
Britzi, M.1
Perucca, E.2
Soback, S.3
-
16
-
-
21844447569
-
A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetic and metabolic profile of topiramate at steady-state in patients with epilepsy
-
in press
-
Mimrod D, Specchio LM, Britzi M, et al. A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetic and metabolic profile of topiramate at steady-state in patients with epilepsy. Epilepsia. 2005. (in press)
-
(2005)
Epilepsia
-
-
Mimrod, D.1
Specchio, L.M.2
Britzi, M.3
-
17
-
-
0036218554
-
Changes in plasma protein binding have little clinical relevance
-
Benet LZ, Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115-121.
-
(2002)
Clin Pharmacol Ther
, vol.71
, pp. 115-121
-
-
Benet, L.Z.1
Hoener, B.2
-
18
-
-
0036771085
-
Inhibition-based metabolic drug-drug interactions: Predictions from in vitro data
-
Yao C, Levy RH. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci. 2002;91:1923-1935.
-
(2002)
J Pharm Sci
, vol.91
, pp. 1923-1935
-
-
Yao, C.1
Levy, R.H.2
-
19
-
-
0036062267
-
Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women
-
Ragueneau-Majelessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia. 2002;43:697-702.
-
(2002)
Epilepsia
, vol.43
, pp. 697-702
-
-
Ragueneau-Majelessi, I.1
Levy, R.H.2
Janik, F.3
-
20
-
-
0037529325
-
Effect of topiramate or carbamazepine on the pharmacokinetics of oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and non-obese female subjects
-
Doose DR, Wang S-S, Padanabhan M, et al. Effect of topiramate or carbamazepine on the pharmacokinetics of oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and non-obese female subjects. Epilepsia. 2003;44:540-549.
-
(2003)
Epilepsia
, vol.44
, pp. 540-549
-
-
Doose, D.R.1
Wang, S.-S.2
Padanabhan, M.3
-
21
-
-
9444267085
-
Functional interaction of intestinal CYP3A4 and P-glycoprotein
-
Kivisto KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol. 2004;18:621-626.
-
(2004)
Fundam Clin Pharmacol
, vol.18
, pp. 621-626
-
-
Kivisto, K.T.1
Niemi, M.2
Fromm, M.F.3
-
22
-
-
2442719906
-
Unmasking the dynamic interplay between efflux transporters and metabolic enzymes
-
Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm. 2004;277:3-9.
-
(2004)
Int J Pharm
, vol.277
, pp. 3-9
-
-
Benet, L.Z.1
Cummins, C.L.2
Wu, C.Y.3
-
23
-
-
13244298981
-
Potential role of drug transporters in the pathogenesis of medically intractable epilepsy
-
Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005;46:224-235.
-
(2005)
Epilepsia
, vol.46
, pp. 224-235
-
-
Kwan, P.1
Brodie, M.J.2
-
24
-
-
0035036730
-
Carbamazepine is not a substrate for P-glycoprotein
-
Owens A, Pirmohamed M, Tettey JN, et al. Carbamazepine is not a substrate for P-glycoprotein. Br Clin Pharamcol. 2001;51:345-349.
-
(2001)
Br Clin Pharamcol
, vol.51
, pp. 345-349
-
-
Owens, A.1
Pirmohamed, M.2
Tettey, J.N.3
-
25
-
-
0036816334
-
P-glycoprtein-mediated efflux of antiepileptic drugs: Preliminary studies in mdr1a knockout mice
-
Sills GJ, Kwan P, Butler E, et al. P-glycoprtein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav. 2002;3:427-432.
-
(2002)
Epilepsy Behav
, vol.3
, pp. 427-432
-
-
Sills, G.J.1
Kwan, P.2
Butler, E.3
-
26
-
-
0141519420
-
Interactions of antiepileptic drugs with human P-glycoprotein in vitro
-
Kerpen WJ, Lindenmaier H, Dormann SM, et al. Interactions of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Ther. 2003;307:262-267.
-
(2003)
J Pharmacol Ther
, vol.307
, pp. 262-267
-
-
Kerpen, W.J.1
Lindenmaier, H.2
Dormann, S.M.3
-
27
-
-
4544383423
-
Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans
-
Giessmann T, May K, Modess C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther. 2004;76:192-200.
-
(2004)
Clin Pharmacol Ther
, vol.76
, pp. 192-200
-
-
Giessmann, T.1
May, K.2
Modess, C.3
|